Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates - Test2 - elhamkhani - TriplyDB

Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates

Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates

http://www.wikidata.org/entity/Q27485369

about

Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users Per-event probability of hepatitis C infection during sharing of injecting equipment Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens.Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index.Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients.Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012.The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014 Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users Traceability, reproducibility and clinical evaluation of Sansure Realtime HCV RNA assay.Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification.Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection Treatment of acute HCV infection.Identifying newly acquired cases of hepatitis C using surveillance: a literature review.Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys.Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection.Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: a population-level tool for incidence estimation.A prospective study of hepatitis C incidence in Australian prisoners.

P2860

Q28476518-DCECCED1-56BD-42C5-830C-7D05E305C378 Q28540414-718D9408-3BE4-4A33-86FB-114C168FFA65 Q30407004-6529E636-4894-49F0-832D-8C3148F059B8 Q30713067-88A70D3F-8D9C-48E6-B3D8-69F2C3136682 Q33631170-D252F73A-AC83-454A-B011-3434AD569C80 Q33650138-9487AA18-3D91-40F8-878A-7AA30E45441C Q33724826-F6D0BCEE-301F-45DD-8934-6F21BCFC7E9C Q33824723-4CD522F9-C175-45FD-B2D9-CFEB384E62EC Q34028058-0569C725-4F7F-424D-8790-C862BB2964E2 Q34101320-02CB3FFF-BD40-4971-AF8C-00681A8FEC89 Q34381567-0640B9E1-B0B5-4BE3-8A4B-7C1C00A3991F Q34785317-EDF37FC7-D316-447A-84D6-135FB747B391 Q34982096-42B39FCB-C829-4D2C-A5AB-A675ECC30EB5 Q35118973-DB413B2C-1042-4EEB-8E81-592A9E0E9AFE Q35138230-DAAA6470-E5F8-42D0-93D7-C278D44D4360 Q35249648-C3735619-F6E6-4B24-9063-6ED3A515783F Q35551683-8D6C3B79-476A-4E79-BB94-F21FC1A0545F Q35593482-F78159DC-9760-4F76-AE53-E8A1356910E0 Q35641523-39C8AC9A-4EAA-458D-8E96-A578E7AACF18 Q35832850-AADEFA94-63A1-49C5-BBE4-9A1E9662E779 Q35864200-E754F8AB-8044-4795-9D3D-EEE308E0DDC1 Q35910953-5CA824B7-BEB2-4EBF-8798-5CFAC5EF4539 Q36058580-53DD42E4-543A-49C3-BA6D-3C553822553B Q36148971-284B607E-8550-4DD0-AA48-28B6225A0D54 Q36200292-CECB0917-DED4-464E-9D3F-A997E896EC49 Q36433960-529608FD-1E0C-4F19-90F0-37FF1E50E16D Q36717008-127E75D0-C525-46E9-A4F8-A829676EA4E9 Q36783211-C5232AAB-13CA-4C83-A200-1A78893A6EF4 Q37042431-F0F94C57-CE21-444D-842C-31F9B3F663C0 Q37288631-D730D921-E1AB-4316-B702-42CC8EA5738E Q37678136-E2BA976C-6427-492E-AA22-C6876C4653CC Q37855530-8C977508-30D3-4705-98F4-A74DCFFDA924 Q38014990-F01B3D8C-87CD-4A9C-B2A6-CC95012EF442 Q38403672-B456E692-92DC-49F3-AD3C-BA7B84E6BB11 Q40466502-23BF6721-D226-44AB-8230-A3459B3B2AB9 Q40563923-9DDC0996-82F6-4617-AB50-9388E79A6154 Q40659995-CDC8D016-926A-4585-9BC9-D192FCDE1937 Q40832940-726CDE5A-3376-43A4-8735-DE762D9A44A2 Q41488562-6FE936E0-150B-42B0-9522-0C04C5E9C068 Q42213249-AA77B83A-B6FA-4D8F-9B9D-17CD6CC48431

P2860

Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates

http://www.wikidata.org/entity/Q27485369

description

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

article scientifique (publié 2008-02)

@fr

articolo scientifico (pubblicato il 2008-02)

@it

artigo científico (publicado na 2008-02)

@pt

artículu científicu espublizáu en 2008

@ast

im Februar 2008 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: February 2008)

@en

vedecký článok (publikovaný 2008-02)

@sk

vetenskaplig artikel (publicerad på 2008-02)

@sv

name

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@ast

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@en

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@nl

type

label

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@ast

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@en

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@nl

prefLabel

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@ast

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@en

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@nl

P1433

Q27485369-CC8C64F4-FEF8-49EC-A93D-E913016F1130

P1476

Q27485369-D8466975-1883-4711-9078-DCF2AB467700

P2093

Q27485369-001BE619-54AD-4B01-8ECB-948AE0FE96C7

Q27485369-07586248-2A31-4DC5-B2A6-46350F07627C

Q27485369-292C1FBB-2A22-498B-A04F-3126FDF07275

Q27485369-4DF0EA35-29E7-4280-AE34-78724219ED19

Q27485369-7000C23D-D83A-41E9-8183-EEC294D27051

Q27485369-8B6433A9-14B9-498A-B93C-7DBEB2EA8CD6

Q27485369-8E1162BA-E533-489B-AF79-93624EB99DEC

Q27485369-AF93B474-7E5B-4831-9BA2-17E5AE7F9F5F

Q27485369-F58056E8-08F7-4873-A8B1-95F103C6208F

P2860

Q27485369-04878635-9444-4D47-B50F-22CA441EBEBC

Q27485369-0A8600F5-A1E6-40D7-95C6-1E26F5D51E3B

Q27485369-0F68F3A5-D6A0-4587-A071-E404C3D1AC82

Q27485369-14A381F9-8CD8-4A69-9B4E-972CD73ED2E8

Q27485369-29F01424-1964-49A2-93A4-9FEB360D4068

Q27485369-29FDBE33-4547-4A67-9BE9-8DCDDD64DACC

Q27485369-2E5E3FBA-E703-413D-93EC-C4FE4020072F

Q27485369-316D6B2B-4A6D-4865-93EE-B9ACDDF345F6

Q27485369-3486D5D6-1FB7-42C8-82BE-E235E8299B97

Q27485369-42668218-0EBD-479A-A9F0-B1BB5AB759B1

P304

Q27485369-2849E59F-B3B1-4B72-837C-5D3BB6764B3F

P31

Q27485369-6DDB843F-D171-4ABC-888B-922B016B859F

P356

Q27485369-D4852E23-1472-41DF-A6B4-2F38AA4FF300

P407

Q27485369-1703F4D1-C215-4B35-A758-3624B1EE3592

P433

Q27485369-7FFDD260-3246-47F9-AE20-443F1B17D3FB

P478

Q27485369-855D9AFA-59E1-4955-8E41-603B4D3EE735

P50

Q27485369-2D31DE1D-E0FF-4AC7-9EAF-EAA33CED9E31

Q27485369-BDAD747F-8325-4844-AD48-F2067C35FA4C

P577

Q27485369-6BBA64E8-F243-45D3-9623-89E62A3D956D

P698

Q27485369-77A1BF61-60BE-4E4D-BE91-12636B23CA70

P932

Q27485369-55477E05-0BF1-42A2-A5BF-0B5F3CFA3021

P356

P1433

Journal of Clinical Microbiology

P1476

Testing Strategy To Identify C ...... To Project HCV Incidence Rates

@en

P2093

Andrew R Moss

http://www.w3.org/2001/XMLSchema#string

Brandee L Pappalardo

http://www.w3.org/2001/XMLSchema#string

Bruce H Phelps

http://www.w3.org/2001/XMLSchema#string

David J Wright

http://www.w3.org/2001/XMLSchema#string

Kimberly Page-Shafer

http://www.w3.org/2001/XMLSchema#string

Leslie H Tobler

http://www.w3.org/2001/XMLSchema#string

Sally Caglioti

http://www.w3.org/2001/XMLSchema#string

Teresa L Wright

http://www.w3.org/2001/XMLSchema#string

Thomas R O'Brien

http://www.w3.org/2001/XMLSchema#string

P2860

Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.

High levels of subgenomic HCV plasma RNA in immunosilent infections

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them.

Tutorial in biostatistics methods for interval-censored data.

Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.

Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients.

US NAT yield: where are we after 2 years?

Global burden of disease (GBD) for hepatitis C.

P304

499-506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JCM.01229-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Michael P. Busch

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18032621

http://www.w3.org/2001/XMLSchema#string

P932

2238141

http://www.w3.org/2001/XMLSchema#string